Weekly Docetaxel Plus Cisplatin as the First-line Therapy for Nasopharyngeal Cancer
The investigators will evaluate weekly docetaxel plus 3-weekly cisplatin regimen as the first-line therapy for recurrent of metastatic nasophayngeal cancer
Nasopharyngeal Cancer
DRUG: Docetaxel, Cisplatin
objective response rate, 6 months after the enrollment of the last patients
number of patients with adverse events, simultaneously when the analysis of primary endpoint
The investigators will evaluate weekly docetaxel plus 3-weekly cisplatin regimen as the first-line therapy for recurrent of metastatic nasophayngeal cancer